DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI E6/E7 ONCOPROTEINS FOR THE TREATMENT OF HPV CANCERS Tania Furst 1, Anna Lechanteur 1,2, Pascale Hubert.

Slides:



Advertisements
Similar presentations
Development of anti-HPV lipoplexes for the treatment of cervical cancer Contact : Anna Lechanteur 1,Tania Furst 1,Brigitte.
Advertisements

Figure 6: Zeta potential, or surface charge, of polyplexes formed with PEI or PEI-VDP was measured by dynamic light scattering. The zeta potentials of.
DEVELOPMENT OF PEG-COATED LIPOPLEXES TO BE INCORPORATED INTO MUCOADHESIVE HEC-SPONGES Tania Furst 1, Anna Lechanteur 1,2, Pascale Hubert 2, Brigitte Evrard.
NUR HIDAYAH OMAR SITI HAJAR ABU BAKAR ALIA ZULAIKHA MOHD HANIF NUR HIDAYAH OMAR SITI HAJAR ABU BAKAR ALIA ZULAIKHA MOHD HANIF.
Joakim Dillner, M.D. Professor Department of Laboratory Medicine Karolinska Institutet Sweden Karolinska Institutet.
Human Papillomaviruses (HPV) such as HPV16 and HPV18 can induce cervical cancer. In this case, the two HPV E6 and E7 oncoproteins are essential players.
Development and optimization of lipoplex vectors for an antisens therapeutic approach in the context of HPV induced lesions Contact :
C. HENDRICKS, L. JANSSEN, R. DELCOMBEL, J. DUBAIL, C. DEROANNE, A. COLIGE Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, Tour.
Nurul Hafizah Mohd Nor, Nur Azhani Zainol Abidin, Nur Liyana Mohd Fozi, Nur Sulaihah Omar & Farahidah Mohamed Pharmaceutical Technology Department, Kulliyyah.
Curcumin, the constituent of Curcuma longa, is considered a very promising anticancer agent due to its potent and pleiotropic antineoplastic activity and.
.  Based on particle size and surface charge characterization studies, both nanoparticles have successfully been synthesized.  Successful conjugation.
Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek, Jae-Woo So, Ji-Sook Hwang, Cheong-Weon.
RESULTS 1) Oligofectamine ® allows effective transfection of siRNA scramble 2) siE6 and siE7 decrease mRNA encoding for both oncoproteins 3) siE7 and association.
Human Papillomaviruses (HPV) such as HPV16 and HPV18 can induce cervical cancer. In this case, the two HPV E6 and E7 oncoproteins are essential players.
Transfection.
The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.
Inhibition of C13orf19 mRNA expression by siRNA in prostate cancer cells * Introduction A high proportion of bladder cancer.
▶ Objective : To know methods that make new cell line through stable transfection 김준섭.
1 Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, Belgium 2 Laboratory of Analytical Chemistry, CIRM, University of.
Formulation and characterisation of lipoplexes Development of a sustained release system containing lipid nanoparticles for intravaginal delivery Development.
DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI-E6/E7 ONCOPROTEINS TO BE INCORPORATED INTO MUCOADHESIVE HEC- SPONGES FOR THE TREATMENT OF HPV CANCERS.
Cat # SL Store at 4 0 C GenJet™ siRNA Transfection Reagent Small 0.5 ml Large 1.0 ml Gaither Drive Gaithersburg, MD FAX
Gene therapy Lecture 8. What is a liposome? ◦ Spherical vesicles with a phospholipid bilayer Hydrophilic Hydrophobic.
Fig.4. (A) Lipoplexes at N/P 2,5 with 0% and 10%PEG in presence of acidic pH. No leakage and no degradation of siRNA when lipoplexes are in acidic environment.
Products > SKNAS Transfection Reagent (Neuroblastoma Cells) Altogen Biosystems offers the SKNAS Transfection Reagent among a host of 100+ cell line specific.
Altogen Biosystems offers the Transfection Reagent for PANC-1 Cells Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection.
Products > 293T/17 Transfection Reagent (Embryonic Kidney Cells, CRL-11268) Altogen Biosystems offers the 293T/17 Transfection Reagent among a host of.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Nanoparticle Engineering: conjugation of peptides via E5-K5
Products > MCF-7 Transfection Reagent (Breast Cancer, HTB-22) Altogen Biosystems offers the MCF-7 Transfection Reagent among a host of 100+ cell line specific.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Dodecaborate clusters forms stable pores in lipid membranes
Products > CFPEo (HTRpC) Transfection Reagent (Trachea Epithelium)
Volume 84, Issue 1, Pages (January 2003)
LIPOSOMES AS DRUG CARRIERS
Products > DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Transfection Reagent GenJet™ In vitro siRNA Small 0.5 ml Large 1.0 ml
Products > LoVo Transfection Reagent (Colon Adenocarcinoma)
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Products > AsPC-1 Transfection Reagent (Pancreatic Beta Cells)
Products > HUH-7 Transfection Reagent (Liver Cancer Cells)
DNA-MEMBRANE RECOGNITIONS: FROM PROTOCELL EVOLUTION TO BIONANOTHERAPY
EFFECT OF STORAGE TEMPERATURE ON THE STABILITY OF TOTAL PARENTERAL NUTRITION ADMIXTURES PREPARED FOR INFANTS Acta Poloniae Pharmaceutica n Drug Research,
Products > SK-N-MC Transfection Reagent (Neuroblastoma Cells)
Liposome Applications —Creative Biostructure. Creative Biostructure established an advanced and novel Liposomes Platform to faciliate research in membrane.
Products > Keratinocyte Transfection Reagent (Keratinocytes)
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
Volume 21, Issue 10, Pages (October 2013)
Functional Investigation of Fas Ligand Expressions in Human Non-Small Cell Lung Cancer Cells and Its Clinical Implications  Yidan Lin, MD, PhD, Lunxu.
Products > HeLa Transfection Reagent (Cervix Adenocarcinoma Cells)
GOLD NANOPARTICLES FOR TARGETING OF STAVUDINE TO MACROPHAGE
Formulation and characterisation of lipoplexes
Yuhong Xu, Sek-Wen Hui, Peter Frederik, Francis C. Szoka 
Products > ZR-75-1 Transfection Reagent (Breast Carcinoma, CRL1500)
Volume 21, Issue 10, Pages (October 2013)
Volume 85, Issue 5, Pages (November 2003)
Masataka Chiba, Makito Miyazaki, Shin’ichi Ishiwata 
Products > HCT-116 Transfection Reagent (Colon Carcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
RESULTS AND DISCUSSION
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
Molecular Therapy - Nucleic Acids
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Volume 86, Issue 2, Pages (February 2004)
2016 Enhanced Synthesis and Purification of PEGylated Liposomes for Targeted Drug Delivery Neil Parikh, Steven Roberts, and Nitin Agrawal
Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications  Tatjana Michel,
Montse Rovira-Bru, David H. Thompson, Igal Szleifer 
Rumwald Leo G Lecaros, Leaf Huang, Tsai-Chia Lee, Yih-Chih Hsu 
Presentation transcript:

DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI E6/E7 ONCOPROTEINS FOR THE TREATMENT OF HPV CANCERS Tania Furst 1, Anna Lechanteur 1,2, Pascale Hubert 2, Brigitte Evrard 1, Géraldine Piel 1 1 Laboratory of Pharmaceutical Technology and Biopharmacy - CIRM, University of Liege, Liege, Belgium 2 Laboratory of Experimental Pathology – GIGA Cancer, University of Liege, Liege, Belgium 1. INTRODUCTION 2. RESULTS AND DISCUSSION 3. CONCLUSION Human Papillomaviruses (HPV), particularly high-risk 16 and 18 genotypes, are responsible for chronic infection of keratinocytes of the uterine cervix mucosa. This infection is associated with the development of cervical cancer by overexpressed oncogenes E6 and E7. Those two encoded oncoproteins interact with tumor suppressor genes p53 and pRb and inactive them, which prevents apoptosis of tumor cells. They are attractive targets for the treatment of cancers induced by HPV. A topical treatment seems to be a promising strategy and has a great clinical interest. The purpose of this study is to develop an efficient delivery system, with siRNA anti-E6/E7, able to protect and transport it through the vaginal mucus and into cancerous cells. Cationic liposomes are used and by charge complementarities with negatively charged siRNA, lipoplexes are formed. To be effective, lipoplexes must meet specific physico-chemical characteristics. Moreover, to facilitate the diffusion through the mucus, lipoplexes are peggylated by the addition of a lipid-PEG Preparation of cationic liposomes and siRNA-lipoplexes Liposomes are prepared by hydration of lipidic film method Lipids : - Cationic DOTAP - Fusogenic DOPE - Cholesterol The mean particle size of empty liposomes is nm (± 5.6), with a low PDI=0.12 (±0.03) and their zeta potential is mV (±6). DOTAP/Chol/DOPE 1/0.75/0.5 Total lipid concentration 5,6mM 2.2. Characterization of lipoplexes Z-average diameter (nm) and zeta potential (mV) of lipoplexes according to N/P ratios (N and P = fixed) Fig.1. Lipoplexes are formed at N/P ratios from 0 to 15 (100nM, 1000µl). From the N/P ratio of 2.5, the diameter is ranged between 170 and 220nm (PDI < 0.1) and the zeta potential remains constant at +50mV. (n=4). Fig.2. (A) Gel retardation assay. The spot observed correspond to free siRNA (control N/P=0). Their intensity decreases when N/P ratio increases. siRNA is nearly totally encapsulated. (B) RiboGreen® assay. Encapsulated siRNA is quantified at day 0, 1 and 5 after the lipoplexes preparation. From the N/P ratio of 1.25, they present more than 95% of encapsulation. This percentage is constant until the N/P ratio of 15. The 3 curves overlap: encapsulation efficiency remains constant up to 5 days. (n=4) Encapsulation efficiency visualised with agarose gel (4%) electrophoresis and quantified using a Quant-iT™ RiboGreen® RNA assay Leakage of siRNA according to the time? 2.3. Preparation and characterization of PEG-coated lipoplexes Post-insertion technique: lipoplexes are peggylated by addition of DSPE-PEG 2000 (in RNAse free water) at different percentages (from 10 to 100mol%of DOTAP), vortexed for 15 seconds and maintained for 1 hour at 37°C. Fig.3. Z-average diameter (nm), PDI and zeta potential (mV) of lipoplexes 1/0.75/0.5 at N/P=2.5 with different % of DSPE-PEG (A) When the % of PEG increases, the diameter is ranged between 150 and 220nm. Up 50%, PDI 0.5. (B) Zeta potential decreases from +50mV to -20mV. (n=3) Fig.4. (A) RiboGreen® assay. siRNA’s encapsulation of lipoplexes 1/0.75/0.5 at N/P=2.5 with 50% of PEG in comparison with unpeggylated lipoplexes at the same N/P ratio, at day 0,1 and 5 after their preparation. Lipoplexes: mean % = 95.3% and lipoplexes-PEG: mean % = 89.6%. (n=4) (B) Z-average diameter of liposomes, lipoplexes and lipoplexes-PEG is constant for 5 days when they are stored at 4°C. (B) 50% (A) 2.5. Transfection efficiency (for more information see poster n° Anna Lechanteur) (A) (B) 2.4. Stability evaluation of lipoplexes (A)(B) Fig.5. Transfection experiment on CasKi cells (HPV16+). Lipoplexes and lipoplexes-PEG have a high % of transfection in comparison with oligoplexes (siRNA+Oligofectamine ® ). Mean Fluorescence Intensity (MFI) is higher for lipoplexes and lipoplexes-PEG than for oligoplexes. (n=3) Lipoplexes 1/0.75/0.5 have good physico-chemical characteristics and the optimal selected N/P ratio is 2.5 : > 95% of encapsulation and no leakage of siRNA up 5 days Z-average diameter of 219,9 nm (±14,8) and zeta potential of +48 mV (±1,7) When DSPE-PEG 2000 is added, the Z-average remains constant while zeta potential decreases  50% of PEG is optimal to obtain slightly positive lipoplexes with high density of PEG in their outer bilayer No significant difference in the encapsulation efficiency between lipoplexes and lipoplexes-PEG 50% and the encapsulation is constant for 5 days Empty liposomes, lipoplexes and lipoplexes-PEG 50% are stable: Z-average diameter is constant for 5 days The % of transfection is > 90% for both lipoplexes and lipoplexes-PEG 50%.  N/P ratio selected = 2.5